Flavoxate

Flavoxate

Clinical data
ATC code	G04BD02 (WHO)
Identifiers
IUPAC name 2-(1-piperidyl)ethyl 3-methyl-4-oxo-2-phenyl-chromene-8-carboxylate
CAS Number	15301-69-6
PubChem CID	3354
DrugBank	APRD00972
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C24H25NO4
Molar mass	391.46 g/mol

WikiDoc Resources for Flavoxate
Articles
Most recent articles on Flavoxate Most cited articles on Flavoxate Review articles on Flavoxate Articles on Flavoxate in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Flavoxate Images of Flavoxate Photos of Flavoxate Podcasts & MP3s on Flavoxate Videos on Flavoxate
Evidence Based Medicine
Cochrane Collaboration on Flavoxate Bandolier on Flavoxate TRIP on Flavoxate
Clinical Trials
Ongoing Trials on Flavoxate at Clinical Trials.gov Trial results on Flavoxate Clinical Trials on Flavoxate at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Flavoxate NICE Guidance on Flavoxate NHS PRODIGY Guidance FDA on Flavoxate CDC on Flavoxate
Books
Books on Flavoxate
News
Flavoxate in the news Be alerted to news on Flavoxate News trends on Flavoxate
Commentary
Blogs on Flavoxate
Definitions
Definitions of Flavoxate
Patient Resources / Community
Patient resources on Flavoxate Discussion groups on Flavoxate Patient Handouts on Flavoxate Directions to Hospitals Treating Flavoxate Risk calculators and risk factors for Flavoxate
Healthcare Provider Resources
Symptoms of Flavoxate Causes & Risk Factors for Flavoxate Diagnostic studies for Flavoxate Treatment of Flavoxate
Continuing Medical Education (CME)
CME Programs on Flavoxate
International
Flavoxate en Espanol Flavoxate en Francais
Business
Flavoxate in the Marketplace Patents on Flavoxate
Experimental / Informatics
List of terms related to Flavoxate

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Flavoxate is an anticholinergic with antimuscarinic effects. Its muscle relaxant properties may be due to a direct action on the smooth muscle rather than by antagonizing muscarinic receptors.

Clinical uses

Flavoxate is used to treat urinary bladder spasms. It is available under the trade name Urispas (Paladin),Uritac by El Saad company in Syria, or under the name Bladderon by Nippon Shinyaku of Japan.

Flavoxate HCl is indicated for symptomatic relief of interstitial cystitis, dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis/urethrotrigonitis.

Adverse Reactions The following adverse reactions have been observed, but there are not enough data to support an estimate of their frequency. Nausea, vomiting, dry mouth vertigo, headache, mental confusion, especially in the elderly, drowsiness, nervousness. tachycardia and palpitation. urticaria and other dermatoses, eosinophilia and hyperpyrexia, increased ocular tension, blurred vision, disturbance in eye accommodation and dysuria.

Contraindications: Flavoxate HCl is contraindicated in patients who have any of the following obstructive conditions: pyloric or duodenal obstruction, obstructive intestinal lesions or ileus, achalasia, gastrointestinal hemorrhage and obstructive uropathies of the lower urinary tract.

Sources

• Brenner, G. M. (2000). Pharmacology. Philadelphia, PA: W.B. Saunders Company. ISBN 0-7216-7757-6
• Canadian Pharmacists Association (2000). Compendium of Pharmaceuticals and Specialties (25th ed.). Toronto, ON: Webcom. ISBN 0-919115-76-4